Genentech 4Q Revenues: $3 billion (+9%) 4Q Earnings: $632 million (+6%) YTD Revenues: $11.7 billion (+26%) YTD Earnings: $2.8 billion (+31%) Comments: U.S. product sales were up 19% to $8.5 billion for the year and $2.2 billion in the quarter, up 7%. Avastin sales for the year were $2.3 billion, up 32%. R&D expenses were $618 million in the quarter, up 11% and $2.4 billion YTD, up 38%. Results include approximately $4 million and $6 million of deferred royalty revenue associa...